| scholarly article | Q13442814 |
| P50 | author | Sitanshu Singh | Q87770080 |
| Seetharama D Jois | Q87770082 | ||
| P2093 | author name string | Rushikesh Sable | |
| Ted Gauthier | |||
| Sandeep Pallerla | |||
| Himgauri Naik | |||
| P2860 | cites work | Humanization of an anti-p185HER2 antibody for human cancer therapy | Q24561842 |
| Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab | Q27640593 | ||
| Structural Evidence for Loose Linkage between Ligand Binding and Kinase Activation in the Epidermal Growth Factor Receptor | Q27664452 | ||
| Cancer statistics, 2013 | Q27860762 | ||
| Untangling the ErbB signalling network | Q27860884 | ||
| An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors | Q28207289 | ||
| Anatomy of hot spots in protein interfaces | Q29616238 | ||
| The third dimension bridges the gap between cell culture and live tissue | Q29616642 | ||
| The ErbB signaling network: receptor heterodimerization in development and cancer | Q29617919 | ||
| ERBB receptors and cancer: the complexity of targeted inhibitors | Q29619520 | ||
| Application of surface plasmon resonance spectroscopy to study G-protein coupled receptor signalling | Q33539281 | ||
| Design, synthesis, and docking studies of peptidomimetics based on HER2-herceptin binding site with potential antiproliferative activity against breast cancer cell lines | Q33835904 | ||
| ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling | Q33886341 | ||
| HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment | Q34111958 | ||
| Development of Herceptin resistance in breast cancer cells | Q34293506 | ||
| Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex | Q34314489 | ||
| Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer | Q35177848 | ||
| Structure-activity relationship of conformationally constrained peptidomimetics for antiproliferative activity in HER2-overexpressing breast cancer cell lines | Q35185574 | ||
| Drug resistance and the microenvironment: nature and nurture | Q35214616 | ||
| Methotrexate (MTX)-cIBR conjugate for targeting MTX to leukocytes: conjugate stability and in vivo efficacy in suppressing rheumatoid arthritis | Q35759924 | ||
| Herceptin: mechanisms of action and resistance | Q36386680 | ||
| Inhibition of protein-protein interaction of HER2-EGFR and HER2-HER3 by a rationally designed peptidomimetic | Q36610755 | ||
| Combining mTOR Inhibitors with Chemotherapy and Other Targeted Therapies in Advanced Breast Cancer: Rationale, Clinical Experience, and Future Directions | Q36629854 | ||
| Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. | Q36710542 | ||
| Hot spots--a review of the protein-protein interface determinant amino-acid residues | Q36839286 | ||
| The effect of HER2 expression on cisplatin-based chemotherapy in advanced non-small cell lung cancer patients. | Q37278752 | ||
| Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer | Q37579647 | ||
| Synthetic therapeutic peptides: science and market | Q37625355 | ||
| The safety and side effects of monoclonal antibodies | Q37715703 | ||
| Structure-activity relationships of peptidomimetics that inhibit PPI of HER2-HER3. | Q37721805 | ||
| EGFR-directed monoclonal antibodies in non-small cell lung cancer | Q38072670 | ||
| Plasma protein binding: from discovery to development | Q38116840 | ||
| Early engineering approaches to improve peptide developability and manufacturability | Q38262021 | ||
| Protein detection using proximity-dependent DNA ligation assays. | Q38289736 | ||
| Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors | Q39004424 | ||
| Activity of anticancer agents in a three-dimensional cell culture model | Q39675257 | ||
| A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy | Q39960692 | ||
| Retro peptide-hybrids as selective inhibitors of the Dengue virus NS2B-NS3 protease. | Q40294145 | ||
| Distinctive alterations of invasiveness, drug resistance and cell-cell organization in 3D-cultures of MCF-7, a human breast cancer cell line, and its multidrug resistant variant | Q40737038 | ||
| The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity | Q41566049 | ||
| Specificity within the EGF family/ErbB receptor family signaling network | Q41721612 | ||
| Rat primary hepatocytes show enhanced performance and sensitivity to acetaminophen during three-dimensional culture on a polystyrene scaffold designed for routine use. | Q42489992 | ||
| Nanoparticles containing anti-inflammatory agents as chemotherapy adjuvants: optimization and in vitro characterization | Q42565516 | ||
| A peptidomimetic with a chiral switch is an inhibitor of epidermal growth factor receptor heterodimerization. | Q44114723 | ||
| Update on in vitro cytotoxicity assays for drug development | Q44748416 | ||
| Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival. | Q46004116 | ||
| Designed peptides with homochiral and heterochiral diproline templates as conformational constraints | Q46586571 | ||
| Crystal structures of peptide enantiomers and racemates: probing conformational diversity in heterochiral Pro-Pro sequences. | Q46706616 | ||
| Comprehensive determination of the cyclic FEE peptide chemical stability in solution. | Q54570477 | ||
| Tech.Sight. Analyzing biomolecular interactions | Q77768954 | ||
| Serum stability of peptides | Q81826448 | ||
| P433 | issue | 2 | |
| P921 | main subject | protein design | Q410814 |
| protein-protein interaction | Q896177 | ||
| P577 | publication date | 2018-02-01 | |
| P1433 | published in | Journal of Peptide Science | Q3186932 |
| P1476 | title | Design of cyclic and d-amino acids containing peptidomimetics for inhibition of protein-protein interactions of HER2-HER3 | |
| P478 | volume | 24 |
| Q90231367 | d-amino Acids in Health and Disease: A Focus on Cancer | cites work | P2860 |
Search more.